Cheng Peng

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Yu Hu, Renchi Yang, Xiaofan Liu, Heng Mei et autres

Abstract Introduction Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, demonstrated promising safety and efficacy in primary immune thrombocytopenia (ITP) patients (pts) in phase 1b/2 trials, with these favorable outcomes subsequently confirmed in double-blinded phase 3 ESLIM-01 study (NCT05029635). This final analysis …

cn, us (code pays fourni par la source)

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou et autres

Abstract Introduction: Hetrombopag has been approved for chronic primary immune thrombocytopenia (ITP) (duration >12 months). However, its efficacy and safety in persistent ITP (duration 3–12 months) remain unexplored. Based on existing clinical data, this post-hoc analysis aimed to evaluate the efficacy and …

hk, cn (code pays fourni par la source)

Aria Gen 2 Pilot Dataset

Kong Chen, James A. Fort, Aria Kang, Jonathan Wittmer et autres

The Aria Gen 2 Pilot Dataset (A2PD) is an egocentric multimodal open dataset captured using the state-of-the-art Aria Gen 2 glasses. To facilitate timely access, A2PD is released incrementally with ongoing dataset enhancements. The initial release features Dia'ane, our primary subject, who …

Effects of intravaginal conjugated oestrogen on pessary continuation for pelvic organ prolapse: multicentre, randomised, double blind, placebo controlled trial

Ying Zhou, Rusha Yin, Yuelun Zhang, Xuemei Wang et autres

Abstract Objective To examine the effect of vaginal oestrogen cream on pessary continuation rates in pelvic organ prolapse. Design Multicentre, randomised, double blind, placebo controlled trial. Setting 12 academic medical centres in China (May 2020-June 2023). Participants Postmenopausal women with symptomatic pelvic …

cn, us (code pays fourni par la source)

Machine Learning to Predict the Occurrence of Distant Organ Involvement in Primary Lymphoma of Bone: A Mixed Cohort Study Based on the SEER Database and Chinese single-center Data

Peng Lü, Peng Yu, Bin Cai, Cheng Peng et autres

Primary lymphoma of bone (PLB) significantly worsens in prognosis with distant organ involvement, leading to decreased survival rates. Early detection and appropriate intervention are critical, yet systematic treatment strategies and predictive models are lacking. This study aims to develop and validate a …

cn (code pays fourni par la source)

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Yu Hu, Renchi Yang, Xiaofan Liu, Heng Mei et autres

Introduction Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, showed a clinically meaningful sustained platelet response with a tolerable safety profile in adults with immune thrombocytopenia (ITP) in a randomized, double-blind, placebo-controlled phase 3 study (ESLIM-01) in China1. Here we reported the …

hk, cn (code pays fourni par la source)

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study

Yu Hu, Xiaofan Liu, Hu Zhou, Shujie Wang et autres

hk, cn (code pays fourni par la source)

Development and validation of a machine learning-based postoperative prognostic model for plasma cell neoplasia with spinal lesions as initial clinical manifestations: a single-center cohort study

Chaoqun You, Junying Ren, Linfei Cheng, Cheng Peng et autres

cn (code pays fourni par la source)

Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study

Shukui Qin, Yusheng Wang, Jun Yao, Yanyan Liu et autres

Background: Chemotherapy-induced thrombocytopenia (CIT) increases the risk of bleeding, necessitates chemotherapy dose reductions and delays, and negatively impacts prognosis. Objectives: This study aimed to evaluate the efficacy and safety of hetrombopag for the management of CIT in patients with advanced solid tumors. …

cn (code pays fourni par la source)

MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner

Ying Liu, Cheng Peng, Weihua Zhao, Lihua Julie Zhu et autres

cn (code pays fourni par la source)

Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study

Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou et autres

hk, cn (code pays fourni par la source)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou et autres

Abstract Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag …

hk, cn (code pays fourni par la source)